Q-omics provides the consensus-scored HOXA6 profile across patient tissues and cancer cell-line models. HOXA6 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, HOXA6 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, HOXA6 RNA expression shows 17,542 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UCEC, KIRC, and KIRP as cancer lineages where HOXA6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HOXA6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HOXA6 survival associations across molecular data types. HOXA6 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HOXA6 RNA expression–survival associations across cancer types. High HOXA6 expression shows unfavorable associations in UCEC, CESC, LGG and LAML, but favorable associations in KIRC and UCS. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for HOXA6 RNA expression.
This table summarizes HOXA6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for HOXA6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HOXA6 shows lower tumor expression in KIRC, THCA and BRCA and higher tumor expression in HNSC, PAAD and CHOL. The KIRC box plot shows higher HOXA6 RNA expression in normal versus tumor tissue (log2 FC = −0.658, t-test p < 0.001).
This table shows molecular features associated with HOXA6 in patient tissues and cancer cell lines. In patient samples, HOXA6 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, HOXA6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and SKIN.
